Holen Sie sich die Stockscreener-App
18.12
0.82%
-0.15
Handel nachbörslich:
18.11
-0.01
-0.06%
Schlusskurs vom Vortag:
$18.27
Offen:
$18.28
24-Stunden-Volumen:
18,519
Relative Volume:
0.33
Marktkapitalisierung:
$823.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.28M
KGV:
-9.0795
EPS:
-1.9957
Netto-Cashflow:
$-57.45M
1W Leistung:
+5.59%
1M Leistung:
-7.41%
6M Leistung:
+9.35%
1J Leistung:
+53.82%
1-Tages-Spanne:
$17.76
$18.28
1-Wochen-Bereich:
$17.35
$18.55
52-Wochen-Spanne:
$10.79
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
18.12 | 823.68M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
(OCS) Trading Advice - news.stocktradersdaily.com
HC Wainwright Increases Oculis (NASDAQ:OCS) Price Target to $32.00 - Defense World
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade - Defense World
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - The Manila Times
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - GlobeNewswire Inc.
Stifel maintains Buy rating, $35 target on Oculis shares By Investing.com - Investing.com South Africa
Stifel maintains Buy rating, $35 target on Oculis shares - Investing.com
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day - TipRanks
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - The Manila Times
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis Completes Enrollment in Late-Stage Diabetic Macular Edema Trials - marketscreener.com
Oculis completes enrollment for pivotal DME treatment trials - Investing.com
Oculis Wraps Up Patient Enrollment in Late-stage Studies of Topical Eye Drug - MarketScreener
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - The Manila Times
REG-Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - TradingView
(OCS) Trading Signals - news.stocktradersdaily.com
A First Look At Oculis Holding AG: Revenues Still Several Years Away (NASDAQ:OCS) - Seeking Alpha
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond - The Manila Times
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - Defense World
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 14.1% in February - Defense World
Oculis' Insider Moves: A Glimpse into the Company's Future? - AInvest
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities - MarketScreener
Insider Buying: Oculis Holding Independent Director Bought CHF326k Of Shares - simplywall.st
Lionel Carnot Spends CHF326k On Oculis Holding Stock - Yahoo Home
Equities Analysts Set Expectations for Oculis Q1 Earnings - The AM Reporter
HC Wainwright Comments on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
Robert W. Baird Boosts Oculis (NASDAQ:OCS) Price Target to $41.00 - Defense World
HC Wainwright Lowers Oculis (NASDAQ:OCS) Price Target to $29.00 - Defense World
Oculis (NASDAQ:OCS) Sees Strong Trading Volume After Analyst Upgrade - Defense World
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update - Informazione.it
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Marketscreener.com
(OCS) Investment Analysis - Stock Traders Daily
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Stifel maintains Buy on Oculis shares, price target at $35 By Investing.com - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating By Investing.com - Investing.com South Africa
Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions - TipRanks
Oculis price target raised to $32 from $31 at BofA - TipRanks
Oculis (NASDAQ:OCS) Shares Gap Down Following Weak Earnings - Defense World
Oculis Holding AG Reports 2024 Financial Results - TipRanks
Oculis Reports 2024 Fourth Quarter Net Loss, Completes $100 Million Equity Financing to Support Pipeline - Vision Monday
Stifel maintains Buy on Oculis shares, price target at $35 - Investing.com
Oculis Holding AG reports results for the quarter ended December 31Earnings Summary - TradingView
Oculis Holding AG Reports 2024 Financial Results and Clinical Progress - TipRanks
Oculis (OCS) Projected to Post Quarterly Earnings on Monday - Defense World
(OCSAW) On The My Stocks Page - news.stocktradersdaily.com
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):